| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 10/26/2026 | ±2.0% | -0.9% | over-priced |
| 07/29/2026 | ±2.4% | -0.3% | over-priced |
| 04/27/2026 | ±2.0% | -0.9% | over-priced |
| 02/12/2026 | ±1.9% | -0.5% | over-priced |
| 10/29/2025 | ±1.7% | -3.0% | under-priced |
| 07/30/2025 | ±1.4% | -1.3% | over-priced |
| 04/30/2025 | ±1.8% | +2.5% | under-priced |
| 02/24/2025 | ±1.8% | -0.3% | over-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q3 FY2026 | $1.69 | $1.4B | $367M |
| Q2 FY2026 | $2.55 | $1.2B | $500M |
| Q1 FY2026 | $2.71 | $1.2B | $526M |
| Q4 FY2025 | — | $1.2B | $507M |
PSA (PSA) reports in 90 days, with the next report estimated for 01/25/2027. Across the last 8 reports, options priced an average ±1.9% earnings move while the stock actually moved 1.2% on average — the market has systematically over-priced PSA's earnings risk. Fundamentals into the print: EPS down 35.5% year-over-year, revenue up 11.6%. QuantLogix's live 5-factor engine currently reads PSA as a neutral at 55/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →